{"id":8875,"date":"2018-03-01T14:59:47","date_gmt":"2018-03-01T14:59:47","guid":{"rendered":"http:\/\/fefac.cat\/empresarial\/?p=8875"},"modified":"2018-03-01T14:59:47","modified_gmt":"2018-03-01T14:59:47","slug":"2-de-cada-5-nous-medicaments-sn-per-a-malalties-m","status":"publish","type":"post","link":"https:\/\/fefac.cat\/empresarial\/2-de-cada-5-nous-medicaments-sn-per-a-malalties-m\/","title":{"rendered":"2 de cada 5 nous medicaments s\u00f3n per a malalties minorit\u00e0ries"},"content":{"rendered":"

El 40% de tots els medicaments aprovats a Europa i els Estats Units que inclouen un nou principi actiu estan indicats per a l'abordatge de patologies minoritàries, segons informa la patronal dels laboratoris, Farmaindustria, amb motiu del Dia Mundial d’aquestes malalties, celebrat el 28 de febrer.<\/p>\n

Les últimes dades procedents de les dues principals agències reguladores del món, l'European Medicines Agency (EMA) i la Food and Drug Administration (FDA), dels Estats Units, corresponents a 2017, confirmen aquesta tendència positiva. En el primer cas, el 40% dels 35 medicaments amb un nou principi actiu que van rebre opinió positiva de l'EMA, és a dir 14, són per al tractament de malalties poc freqüents.<\/p>\n

L’EMA destaca les aportacions terapèutiques dels nous fàrmacs orfes, entre els quals figuren medicaments contra patologies considerades rares com la queratitis neurotròfica, el neuroblastoma o la síndrome carcinoide, entre d'altres.<\/p>\n

Pel que fa als Estats Units, un total de 18 medicaments, que representen el 39% de les noves molècules aprovades per la FDA durant l'any passat, són teràpies dirigides a malalties poc freqüents (que afecten a menys de 200.000 ciutadans en el conjunt dels Estats Units). Entre aquests nous medicaments, la FDA destaca un nou fàrmac per tractar una forma específica de la malaltia de Batten i un altre dirigit a prevenir o reduir els episodis hemorràgics en pacients amb un tipus concret d'hemofília A.<\/p>\n

“Aquests bons resultats en medicaments orfes no són aliens a les polítiques de protecció de la propietat industrial aplicades a aquests fàrmacs, ja que han afavorit notablement la seva investigació i desenvolupament en benefici de tots”, explica el director del Departament Tècnic de Farmaindustria, Emili Esteve.<\/p>\n

Segons la seva opinió, "tot i que queda molt camí per recórrer, les dades sobre els nous tractaments disponibles per a combatre les malalties poc freqüents són esperançadors i demostren que si tots els agents implicats (indústria, administracions, professionals sanitaris, centres de recerca, hospitals, etc.) continuem treballant junts dins d'un marc legal afavoridor d’investigació, seguirem aconseguint bons resultats per als pacients en els propers anys”.<\/p>\n","protected":false},"excerpt":{"rendered":"

El 40% de tots els medicaments aprovats a Europa i els Estats Units que inclouen un nou principi actiu estan indicats per a l'abordatge de patologies minoritàries, segons informa la […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[11,12,13,14,15,101],"tags":[180,233],"class_list":["post-8875","post","type-post","status-publish","format-standard","hentry","category-fefac","category-afb","category-afet","category-afell","category-agfe","category-sanitaria","tag-farmaindustria","tag-malalties-rares"],"yoast_head":"\n2 de cada 5 nous medicaments s\u00f3n per a malalties minorit\u00e0ries - FEFAC<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fefac.cat\/empresarial\/2-de-cada-5-nous-medicaments-sn-per-a-malalties-m\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"2 de cada 5 nous medicaments s\u00f3n per a malalties minorit\u00e0ries - FEFAC\" \/>\n<meta property=\"og:description\" content=\"El 40% de tots els medicaments aprovats a Europa i els Estats Units que inclouen un nou principi actiu estan indicats per a l'abordatge de patologies minoritàries, segons informa la […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fefac.cat\/empresarial\/2-de-cada-5-nous-medicaments-sn-per-a-malalties-m\/\" \/>\n<meta property=\"og:site_name\" content=\"FEFAC\" \/>\n<meta property=\"article:published_time\" content=\"2018-03-01T14:59:47+00:00\" \/>\n<meta name=\"author\" content=\"qabh859\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"qabh859\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/2-de-cada-5-nous-medicaments-sn-per-a-malalties-m\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/2-de-cada-5-nous-medicaments-sn-per-a-malalties-m\\\/\"},\"author\":{\"name\":\"qabh859\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#\\\/schema\\\/person\\\/03012b2506772bd65738ce781a3947f7\"},\"headline\":\"2 de cada 5 nous medicaments s\u00f3n per a malalties minorit\u00e0ries\",\"datePublished\":\"2018-03-01T14:59:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/2-de-cada-5-nous-medicaments-sn-per-a-malalties-m\\\/\"},\"wordCount\":419,\"keywords\":[\"Farmaindustria\",\"Malalties Rares\"],\"articleSection\":[\"FEFAC\",\"AFB\",\"AFET\",\"AFELL\",\"AGFE\",\"Sanit\u00e0ria\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/2-de-cada-5-nous-medicaments-sn-per-a-malalties-m\\\/\",\"url\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/2-de-cada-5-nous-medicaments-sn-per-a-malalties-m\\\/\",\"name\":\"2 de cada 5 nous medicaments s\u00f3n per a malalties minorit\u00e0ries - FEFAC\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#website\"},\"datePublished\":\"2018-03-01T14:59:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#\\\/schema\\\/person\\\/03012b2506772bd65738ce781a3947f7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/2-de-cada-5-nous-medicaments-sn-per-a-malalties-m\\\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/2-de-cada-5-nous-medicaments-sn-per-a-malalties-m\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/2-de-cada-5-nous-medicaments-sn-per-a-malalties-m\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"2 de cada 5 nous medicaments s\u00f3n per a malalties minorit\u00e0ries\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#website\",\"url\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/\",\"name\":\"FEFAC\",\"description\":\"Federaci\u00f3 d'Associacions de Farm\u00e0cies de Catalunya\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#\\\/schema\\\/person\\\/03012b2506772bd65738ce781a3947f7\",\"name\":\"qabh859\",\"url\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/author\\\/qabh859\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"2 de cada 5 nous medicaments s\u00f3n per a malalties minorit\u00e0ries - FEFAC","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fefac.cat\/empresarial\/2-de-cada-5-nous-medicaments-sn-per-a-malalties-m\/","og_locale":"ca_ES","og_type":"article","og_title":"2 de cada 5 nous medicaments s\u00f3n per a malalties minorit\u00e0ries - FEFAC","og_description":"El 40% de tots els medicaments aprovats a Europa i els Estats Units que inclouen un nou principi actiu estan indicats per a l'abordatge de patologies minoritàries, segons informa la […]","og_url":"https:\/\/fefac.cat\/empresarial\/2-de-cada-5-nous-medicaments-sn-per-a-malalties-m\/","og_site_name":"FEFAC","article_published_time":"2018-03-01T14:59:47+00:00","author":"qabh859","twitter_card":"summary_large_image","twitter_misc":{"Escrit per":"qabh859","Temps estimat de lectura":"2 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fefac.cat\/empresarial\/2-de-cada-5-nous-medicaments-sn-per-a-malalties-m\/#article","isPartOf":{"@id":"https:\/\/fefac.cat\/empresarial\/2-de-cada-5-nous-medicaments-sn-per-a-malalties-m\/"},"author":{"name":"qabh859","@id":"https:\/\/fefac.cat\/empresarial\/#\/schema\/person\/03012b2506772bd65738ce781a3947f7"},"headline":"2 de cada 5 nous medicaments s\u00f3n per a malalties minorit\u00e0ries","datePublished":"2018-03-01T14:59:47+00:00","mainEntityOfPage":{"@id":"https:\/\/fefac.cat\/empresarial\/2-de-cada-5-nous-medicaments-sn-per-a-malalties-m\/"},"wordCount":419,"keywords":["Farmaindustria","Malalties Rares"],"articleSection":["FEFAC","AFB","AFET","AFELL","AGFE","Sanit\u00e0ria"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/fefac.cat\/empresarial\/2-de-cada-5-nous-medicaments-sn-per-a-malalties-m\/","url":"https:\/\/fefac.cat\/empresarial\/2-de-cada-5-nous-medicaments-sn-per-a-malalties-m\/","name":"2 de cada 5 nous medicaments s\u00f3n per a malalties minorit\u00e0ries - FEFAC","isPartOf":{"@id":"https:\/\/fefac.cat\/empresarial\/#website"},"datePublished":"2018-03-01T14:59:47+00:00","author":{"@id":"https:\/\/fefac.cat\/empresarial\/#\/schema\/person\/03012b2506772bd65738ce781a3947f7"},"breadcrumb":{"@id":"https:\/\/fefac.cat\/empresarial\/2-de-cada-5-nous-medicaments-sn-per-a-malalties-m\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fefac.cat\/empresarial\/2-de-cada-5-nous-medicaments-sn-per-a-malalties-m\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fefac.cat\/empresarial\/2-de-cada-5-nous-medicaments-sn-per-a-malalties-m\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fefac.cat\/empresarial\/"},{"@type":"ListItem","position":2,"name":"2 de cada 5 nous medicaments s\u00f3n per a malalties minorit\u00e0ries"}]},{"@type":"WebSite","@id":"https:\/\/fefac.cat\/empresarial\/#website","url":"https:\/\/fefac.cat\/empresarial\/","name":"FEFAC","description":"Federaci\u00f3 d'Associacions de Farm\u00e0cies de Catalunya","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fefac.cat\/empresarial\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Person","@id":"https:\/\/fefac.cat\/empresarial\/#\/schema\/person\/03012b2506772bd65738ce781a3947f7","name":"qabh859","url":"https:\/\/fefac.cat\/empresarial\/author\/qabh859\/"}]}},"_links":{"self":[{"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/posts\/8875","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/comments?post=8875"}],"version-history":[{"count":0,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/posts\/8875\/revisions"}],"wp:attachment":[{"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/media?parent=8875"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/categories?post=8875"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/tags?post=8875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}